GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma

$300M upfront: GSK licensed linerixibat to Alfasigma for cholestatic pruritus in primary biliary cholangitis (PBC), with additional milestone payments contingent on development/commercial milestones while the drug awaits FDA review. The transaction secures near-term cash for GSK and transfers commercialization risk and costs to Alfasigma, a modestly positive catalyst for both companies pending the FDA outcome.

Analysis

$300M upfront: GSK licensed linerixibat to Alfasigma for cholestatic pruritus in primary biliary cholangitis (PBC), with additional milestone payments contingent on development/commercial milestones while the drug awaits FDA review. The transaction secures near-term cash for GSK and transfers commercialization risk and costs to Alfasigma, a modestly positive catalyst for both companies pending the FDA outcome.